Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Posts Near Flat Revenues for Q1

SAN FRANCISCO, April 25 - Invitrogen on Thursday posted near flat revenues for the first quarter 2002.


For the three months ended March 31, the company reported revenues of $159.9 million, compared with $160.7 million in the same period one year ago.


Invitrogen said that it had a pro forma profit, excluding merger related amortization and costs, and net of tax, of $25.1 million, or $.46 per share, for the first quarter of 2002, compared to $24 million, or $.45 per share, for the year-ago period.


Under standard rules, Invitrogen reported net income of $14.5 million, or $.27 a share, compared to a loss of $39.6 million, or $.76 a share, in the same period one year ago.


Invitrogen said it has $693.7 million in cash and cash equivalents and $148.8 million in short-term investments held-to-maturity, compared to $878.2 million and $99.6 million respectively as of December 31, 2001.


The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.